MedPath

Clinical efficacy and safety of CollaDerm in the management of diabetic foot ulcers: randomized controlled trial

Not Applicable
Completed
Conditions
Diseases of the skin and subcutaneous tissue
Registration Number
KCT0003802
Lead Sponsor
Yonsei University Health System, Severance Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
38
Inclusion Criteria

1) patients with type 1 or type 2 diabetes over 20 years of age
2) Wagner classification of grade 1 and 2 patients with lower limb ulcer
3) Ulcer size = 1 ?
4) Patients who had diabetic foot ulcer for more than 6 weeks
5) If there is any of the following three conditions in the leg with a target foot ulcer at the previous treatment day (V1)
? One or more of the foot arterial sounds of the ankle joint region through Doppler examination
? Percutaneous oxygen partial pressure greater than 30 mmHg
? When pulse is palpable
6) Patients who were negative for microbiological culture after appropriate antibiotic treatment even without systemic or local infection or with infection
7) Subjects who have received sufficient explanations for this clinical trial and then signed the agreement

Exclusion Criteria

1) Pregnant or lactating women and women of childbearing age who refuse a contraception during the study
2) Patients with sepsis, osteomyelitis, abscess, gangrene or soft tissue infection treated unsuccessfully with debridement
3) Patients diagnosed as venous insufficiency, diabetic fatty necrosis and ulcer with deep vein thrombosis
4) Patients had connective tissue disorder that interferes with wound healing, such as rheumatoid arthritis, systemic lupus erythematosus
5) Patients diagnosed as Charcot–Marie–Tooth disease or sickle cell disesase
6) Patients with chronic wasting disease who are not currently being treated
7) Patients had poor prognosis diseases including malignant tumors
8) Patients had corticosteroids, immunosuppressants, radiation therapy or chemotherapy
9) Patients with hypersensitivity to the constituents of the substance or storage solution used in the manufacturing process
10) Patients known hypersensitivity to bovine-derived components
11) Patients had mental disorder, drugs or alcohol addiction and could not understand the present study
12) Patients whose life is short
13) If the use of a prohibited drug is anticipated during the trial period
14) If patients are taking medicines for other clinical trials within 30 days of participating in this clinical trial
15) Patients not suitable for research based on the researcher’s decision

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Complete healing rates;Adverse reactions and laboratory tests, signs of vitality
Secondary Outcome Measures
NameTimeMethod
Size of ulcer;Depth of ulcer
© Copyright 2025. All Rights Reserved by MedPath